The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients

Maizumi Furuse1, Shuhei Hosomi1*, Yu Nishida1, Shigehiro Itani1, Yuji Nadatani1, Shusei Fukunaga1, Koji Otani1, Fumio Tanaka1, Yasuaki Nagami1, Koichi Taira1, Noriko Kamata1, Toshio Watanabe1, Kenji Watanabe2, Yasuhiro Fujiwara1

1 Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan, 2 Department of Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

* m1265271@med.osaka-cu.ac.jp

Abstract

Tacrolimus (Tac) is an effective remission inducer of refractory ulcerative colitis (UC). Gene polymorphisms result in interindividual variability in Tac pharmacokinetics. In this study, we aimed to examine the relationships between gene polymorphisms and the metabolism, pharmacokinetics, and therapeutic effects of Tac in patients with UC. Forty-five patients with moderate-to-severe refractory UC treated with Tac were retrospectively enrolled. Genotyping for cytochrome P450 (CYP) 3A4*1G, CYP3A5*3, CYP2C19*2, CYP2C19*3, nuclear receptor subfamily 1 group I member 2 (NR1I2)–25385C>T, ATP-binding cassette subfamily C member 2 (ABCC2)–24C>T, ABCC2 1249G>A, and ABCC2 3972C>T was performed. Concentration/dose (C/D) ratio, clinical therapeutic effects, and adverse events were evaluated. The C/D ratio of Tac in UC patients with the CYP3A4*1G allele was statistically lower than in those with the CYP3A4*1/*1 allele (P = 0.005) and significantly lower in patients with CYP3A5*1 than those with CYP3A5*1 (P < 0.001). Among patients with the CYP3A4*1G allele, the C/D ratio was significantly lower in patients with CYP3A5*1 than in those with CYP3A5*3 (P = 0.001). Patients with the NR1I2–25385C>T genotype presented significantly more overall adverse events than those with the C/T or T/T genotype (P = 0.03). Although CYP3A4*1G and CYP3A5*3 polymorphisms were related to Tac pharmacokinetics, CYP3A5 presented a stronger effect than CYP3A4. The NR1I2–25385C>T genotype was related to the overall adverse events. The evaluation of these polymorphisms could be useful in the treatment of UC with Tac.

Introduction

Ulcerative colitis (UC), a chronic inflammatory disease of unknown etiology, occurs in the colorectum [1]. Although corticosteroid therapy is the mainstay option for inducing UC remission, 33% of severe active UC cases have been reported to be refractory to corticosteroids [2]. Calcineurin inhibitors such as cyclosporine and tacrolimus (Tac) [3] are effective remission...
inducers for refractory UC. The effective and safe doses of Tac differ among individuals as the therapeutic range of Tac is narrow. Therefore, close monitoring of the plasma drug concentration is necessary.

Cytochrome P-450 (CYP) 3A, a major member of the CYP enzyme subfamily, is predominantly responsible for the metabolism of Tac via the demethylation of 13-α-demethyltacrolimus [4]. The mRNAs and proteins of CYP3A4 and CYP3A5, two major enzymes of the CYP3A subfamily, are abundantly expressed in the adult liver [5]. Interindividual variability in Tac metabolism is mainly due to single nucleotide polymorphisms (SNPs) in CYP3A5, and dosing recommendations for Tac based on the CYP3A5 genotype have been published in the field of organ and stem cell transplantation [6]. A SNP at position 6986A within intron 3 of CYP3A5, which is referred to as CYP3A5*3 (rs776746, 6986A > G), can reduce the expression of the functional CYP3A5 protein because of a splicing disorder [7]. Therefore, individuals with at least one CYP3A5*1 allele are known as CYP3A5 expressers and those with CYP3A5*3/*3 genotype are known as CYP3A5 non-expressers [8]. CYP3A5 expressers have lower dose-adjusted Tac blood concentrations and require higher Tac doses than CYP3A5 non-expressers [9–11]. Despite these findings, the interindividual variability in Tac pharmacokinetics has not been adequately explained [12, 13], as the pharmacokinetics vary among CYP3A5 expressers and non-expressers. Therefore, polymorphisms in other candidate genes have been investigated to explain the interindividual variability in Tac pharmacokinetics [14].

CYP3A4, which encodes CYP3A4, another major enzyme of the CYP3A subfamily involved in drug pharmacokinetics, has several SNPs related to the metabolic activity of CYP3A4 [15, 16], such as the CYP3A4*1B (rs2740574, −392A>G) [17] and CYP3A4*1G (rs2242480, 20230C>T) alleles with increased CYP3A4 enzyme activity [18–20] and the CYP3A4*22 (rs35599367, 15389C>T) allele with reduced CYP3A4 enzyme activity [21]. The mutation frequency of CYP3A4*1G is relatively high in the Japanese population [22], but Japanese individuals do not have the CYP3A4*1B and CYP3A4*22 alleles [9, 21]. Other gene polymorphisms related to drug metabolism can influence the pharmacokinetics of Tac. Pregnane X receptor (PXR, encoded by NR1I2) is involved in the transcriptional regulation of CYP enzymes, including CYP3A4 and CYP3A5. In fact, the induction of CYP3A4 by the NR1I2 −25385T (rs3814055, −25385C>T) allele has been reported to be higher than that by the NR1I2 −25385C/C allele [23], resulting in lower Tac concentrations [24]. Although CYP2C19 may not directly affect Tac pharmacokinetics, CYP2C19 polymorphisms can affect the pharmacokinetics of Tac when co-administered with voriconazole [25, 26]. Regarding drug efflux, a recent study showed that the polymorphism of ABCC2, which encodes multidrug resistance-associated protein 2 that plays a role in Tac efflux into the lumen in association with CYP3A in the small intestine [27], can affect Tac pharmacokinetics [28]. However, the relationship between these SNPs, except CYP3A5*3, and the pharmacokinetics and effects of Tac in patients with UC has not been clarified. Therefore, the aim of this study was to investigate the relationship of CYP3A4, CYP2C19, NR1I2, and ABCC2 polymorphisms as well as CYP3A5*3/*3 with the pharmacokinetics and therapeutic effects of Tac in patients with UC. Furthermore, we examined the relationship between gene polymorphisms and adverse events in patients with UC.

Materials and methods

Patient selection

We retrospectively enrolled 47 Japanese patients with moderate-to-severe UC. All patients were treated with Tac for remission induction in the University Hospital between January 2009 and January 2018. Demographic characteristics, laboratory results, and medication history were obtained from the medical records.
Treatment protocol and evaluation of treatment efficacy

The initial Tac dose was generally 0.05 mg/kg/day and orally administered twice a day at 12-h intervals. Blood Tac concentration was measured by either an affinity column-mediated immunoassay (from January 2009 to January 2013), a chemiluminescent immunoassay (from February 2013 to June 2014), or an electro-chemiluminescence immunoassay (July 2014 to January 2018) in the in-hospital laboratory. In most patients, to monitor the blood Tac concentration, trough Tac level was measured three times a week in the first 2 weeks. The dose was adjusted to achieve a high trough level of 10–15 ng/mL in the first 2 weeks. Two weeks after administration, the dose was adjusted to achieve a low trough level of 5–10 ng/mL.

Clinical disease activity was assessed using the partial Mayo score (sum of 3 subscores of the Mayo score without the endoscopic findings) [29] at 1, 2, and 4 weeks. Clinical response was defined as a reduction in the partial Mayo score by ≥2 points accompanied by a decrease of at least 30% from baseline and a decrease in the rectal bleeding subscore of ≥1 or an absolute rectal bleeding subscore of 0 or 1. Safety was evaluated using physical findings and blood tests based on medical records for 12 weeks.

Ethical considerations

This study was approved by the Ethics Committee of Osaka City University Graduate School of Medicine (approval number: 3293). Written informed consent was obtained from all patients at the start of this study. All data were fully anonymized before we accessed them.

Genotyping

DNA was isolated from the patients’ peripheral blood samples in ethylenediaminetetraacetic acid using the QIamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). We selected the SNPs that have been reported to potentially affect the pharmacokinetics of Tac, as described in the Introduction. Finally, genotyping was performed for the following nine SNPs: CYP3A4 rs2242480 C>T (CYP3A4*1G allele), CYP3A4 rs4646438 →T (CYP3A4*6 allele), CYP3A5 rs776746 C>T (CYP3A5*3 allele), CYP2C19 rs4244285 G>A (CYP2C19*2 allele), CYP2C19 rs4986893 G>A (CYP2C19*3 allele), NR1I2 rs3814055 C>T, ABCC2 rs717620 C>T (–24), ABCC2 rs2273697 G>A (1249), and ABCC2 rs3740066 G>C (3972). It was performed using TaqMan SNP genotyping assay kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions.

Statistical analysis

The concentration and dose ratio (C/D ratio) [(ng/mL)/(mg/kg)] were calculated as Tac trough levels (ng/mL) multiplied by body weight (kg) and divided by Tac dose (mg), and it was used as an index of Tac metabolism.

All SNPs were tested for deviation from the Hardy–Weinberg equilibrium and p > 0.05 (chi-squared test) was considered to indicate equilibrium. For pairwise linkage disequilibrium (LD) analysis, r² was calculated using Haploview software (Broad Institute, Cambridge, MA).

Continuous variables are summarized as mean and standard deviation (SD). Unpaired t-test was used to assess the differences in mean values. Chi-squared test or Fisher’s exact test was performed to evaluate the differences in clinical data between each group. Fisher’s exact test was applied to small samples. Multivariate analyses were performed using a linear logistic regression model to identify factors associated with the therapeutic effect of Tac. The association between gene polymorphisms and Tac pharmacokinetics was analyzed without and with correction for age and the partial Mayo score. These statistical analyses were performed using
EZR (Saitama Medical Center, Jichi Medical University), a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). Results with a p value of <0.05 were considered statistically significant.

## Results

### Baseline characteristics

There were 47 patients with moderate-to-severe UC; they were all Japanese. Of these patients, two were excluded owing to follow-up loss. Finally, 45 patients were eligible for this retrospective study.

Table 1 shows the baseline characteristics of the 45 patients, including 24 men (53%). The mean age was 43 years and the mean disease duration was 6 years. The number of patients who received systemic corticosteroids before starting Tac was 30 (67%). The mean corticosteroid dose was 22 mg. Other treatments were antitumor necrosis factor (TNF)-α antibodies in seven patients (16%) and thiopurines in eight patients (18%). The mean partial Mayo score was 7.

### Frequency of genotypes

Table 2 shows the allele and genotype frequencies of the nine SNPs. Finally, we analyzed eight SNPs in this study because no patient had the CYP3A4*6 allele. The allele frequencies of the eight SNPs did not deviate from the Hardy–Weinberg equilibrium. However, there was a strong degree of pairwise LD between the CYP3A5*3 and CYP3A4*1G polymorphisms ($r^2 = 0.859$).

---

**Table 1. Baseline characteristics of patients.**

|                                | All patients |
|--------------------------------|--------------|
| Number of patients             | 45           |
| Age, mean ± SD                 | 43 ± 16.9    |
| Male, n (%)                    | 24 (53)      |
| Body weight, mean ± SD, kg     | 55 ± 9.7     |
| Disease duration, mean ± SD, years | 6 ± 7.9     |
| Disease location               |              |
| Pancolitis, n (%)              | 34 (76)      |
| Left-sided colitis, proctitis, n (%) | 11 (24)    |
| Response to corticosteroid therapy |          |
| Resistant, n (%)               | 19 (42)      |
| Dependent, n (%)               | 26 (58)      |
| Corticosteroid dose, mean ± SD, mg$^\dagger$ | 22 ± 23.1 |
| Anti-TNF-α antibody (or biologics) refractory disease, n (%) | 7 (16) |
| Thiopurine treatment, n (%)    | 8 (18)       |
| Food intake (yes/no)           | 6/39         |
| Hemoglobin, mean ± SD, g/dL    | 12 ± 2.1     |
| Serum albumin, mean ± SD, g/dL | 3 ± 0.7      |
| C-reactive protein, mean ± SD, mg/dL | 4 ± 5.1   |
| Partial Mayo score before starting Tac therapy, mean ± SD | 7 ± 1.3 |

$^\dagger$The listed value is the prednisolone equivalent.

SD: standard deviation; TNF: tumor necrosis factor

https://doi.org/10.1371/journal.pone.0250597.t001
As previously reported [8], the CYP3A5 genotype was divided into CYP3A5*1/*1 + *1G/*1G (expressers) and CYP3A5*3/*3 (non-expressers). The CYP3A4 genotype was divided into CYP3A4*1/*1 and CYP3A*1G/*1G + *1G/*1G, as reported previously [18].

Association of gene polymorphisms with tacrolimus pharmacokinetics

To reveal the association between these gene polymorphisms and Tac pharmacokinetics, we investigated the days required to achieve the target trough level, daily tacrolimus dose, and C/D ratio in the high trough phase (Table 3).

There were no significant associations of NR1I2, CYP2C19, and ABCC2 polymorphisms with the C/D ratio in the high trough phase. Patients with the CYP3A4*1G allele required significantly longer duration and higher Tac daily dose to achieve the target trough levels than those with the CYP3A4*1/*1 allele (P = 0.002 and P = 0.019, respectively). The C/D ratio was significantly lower in patients with the CYP3A4*1G allele than in those with the CYP3A4*1/*1 allele (P = 0.005). Regarding CYP3A5 polymorphism, CYP3A5 expressers required...
Table 3. Relationship between genetic polymorphism and pharmacokinetics.

| Gene   | Position | Genotype | n   | Days required to achieve target trough levels<sup>1</sup> | Daily dose when reached high trough<sup>1</sup> | C/D ratio when reached high trough<sup>1</sup> |
|--------|----------|----------|-----|-------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
|        |          |          |     | day, mean ± SD | P value | mg/kg, mean ± SD | P value | ng/mL per mg/kg, mean ± SD | P value |
| CYP3A4 | *1G      | *1/1<sup>1</sup> 1 | 30  | 6.9 ± 2.6      | 0.002<sup>**</sup> | 4.3 ± 3.1   | 0.019<sup>†</sup> | 146.5 ± 68.1 | 0.005<sup>‡</sup> |
|        |          | *1/1<sup>1</sup> 1/1<sup>1</sup> 1G 1G | 15  | 10.9 ± 4.0     |          | 7.0 ± 3.8   |          | 87.9 ± 46.1 |          |
| CYP3A5 | *3       | *1/1<sup>1</sup> 1/1<sup>1</sup> 3 | 13  | 7.8 ± 3.6      | 0.002<sup>**</sup> | 11.7 ± 3.8 | <0.0001<sup>***</sup> | 74.9 ± 32.6 | <0.0001<sup>***</sup> |
|        |          | *3/3<sup>3</sup> 1G 3 | 32  | 4.2 ± 3.1      |          | 6.8 ± 2.6   |          | 148.2 ± 66.3 |          |
| CYP2C19 | *2      | GG  | 28  | 5.8 ± 3.9      | 0.17    | 7.7 ± 2.8   | 0.21    | 134.9 ± 67.9 | 0.32    |
|        |          | GA + AA | 17  | 4.3 ± 3.0      |          | 9.1 ± 4.7   |          | 114.0 ± 66.0 |          |
| CYP2C19 | *3      | GG  | 35  | 5.4 ± 4.0      | 0.66    | 8.4 ± 3.9   | 0.54    | 131.0 ± 73.4 | 0.46    |
|        |          | GA + AA | 10  | 4.8 ± 1.7      |          | 7.6 ± 2.8   |          | 112.9 ± 38.2 |          |
| ABCC2  | –24     | CC  | 32  | 4.9 ± 3.1      | 0.33    | 7.9 ± 3.9   | 0.39    | 129.0 ± 71.7 | 0.76    |
|        |          | CT + TT | 13  | 6.1 ± 4.6      |          | 9.0 ± 3.0   |          | 122.0 ± 56.8 |          |
| ABCC2  | 1249    | GG  | 34  | 5.5 ± 3.8      | 0.36    | 8.3 ± 3.8   | 0.80    | 130.5 ± 64.7 | 0.54    |
|        |          | GA + AA | 11  | 4.4 ± 2.9      |          | 8.0 ± 3.3   |          | 116.2 ± 76.6 |          |
| ABCC2  | 3972    | CC  | 30  | 4.9 ± 3.2      | 0.42    | 7.9 ± 4.0   | 0.33    | 129.5 ± 72.1 | 0.73    |
|        |          | CT + TT | 15  | 5.9 ± 4.3      |          | 9.0 ± 2.8   |          | 122.1 ± 58.2 |          |
| NR1I2  | –25385  | CC  | 26  | 5.5 ± 3.2      | 0.59    | 9.1 ± 3.9   | 0.075   | 117.8 ± 66.4 | 0.29    |
|        |          | CT + TT | 19  | 4.9 ± 4.2      |          | 7.1 ± 3.0   |          | 139.6 ± 68.0 |          |

* = P < 0.05,
** = P < 0.01,
*** = P < 0.001

<sup>1</sup>Target trough levels mean high trough level of 10 to 15 ng/mL for first two weeks low trough level of 5 to 10 ng/mL after 2 weeks of administration.

<sup>2</sup>High trough means trough level more than 10 ng/mL.

ABCC2: ATP binding cassette subfamily C member 2; C/D ratio: Tacrolimus concentration and dose ratio; CYP2C19: cytochrome P450 family 2 subfamily C member 19; CYP3A4: cytochrome P450 family 2 subfamily A member 4; CYP3A5: cytochrome P450 family 2 subfamily A member 5; NR1I2, nuclear receptor subfamily 1 group 1 member 2

https://doi.org/10.1371/journal.pone.0250597.t003

significantly longer duration and higher Tac daily dose to achieve the target trough level than CYP3A5 non-expressers (P = 0.002 and P < 0.0001, respectively). The C/D ratio was significantly lower in CYP3A5 expressers than in CYP3A5 non-expressers (P < 0.001).

Furthermore, we investigated the interaction effect between CYP3A4<sup>1G</sup> and CYP3A5<sup>3</sup> polymorphisms on Tac pharmacokinetics, as there was a strong degree of pair-wise LD between CYP3A5<sup>3</sup> and CYP3A4<sup>1G</sup> polymorphisms (S1 Table). Among CYP3A5 expressers, none had CYP3A4<sup>1G</sup>. Among 15 patients with the CYP3A4<sup>1G</sup> allele, the C/D ratio was significantly lower in CYP3A5 expressers than in CYP3A5 non-expressers (P = 0.001). This suggests that CYP3A5 polymorphism could have a stronger effect on Tac pharmacokinetics than CYP3A4 polymorphism.

**Relationship between CYP3A4<sup>1G</sup> and CYP3A5<sup>3</sup> polymorphisms and therapeutic effects**

We evaluated the therapeutic effects of Tac at 1, 2, and 4 weeks in patients with each genetic polymorphism. There were no significant associations between NR1I2, CYP2C19, and ABCC2 polymorphisms and therapeutic effects (data not shown). Patients with CYP3A4<sup>1/1<sup>G</sup></sup> showed a significantly higher therapeutic effect than those with CYP3A4<sup>1/1<sup>G</sup>+1/1<sup>G</sup></sup> at 1 week after Tac initiation (Fig 1A). Similarly, CYP3A5 non-expressers showed a significantly higher therapeutic effect than CYP3A5 expressers at 1 week after Tac initiation (Fig 1B).
CYP3A4 and CYP3A5 polymorphisms, patient background, concomitant thiopurine treatment, and laboratory data before Tac induction were analyzed to identify factors affecting the therapeutic effects of Tac. The univariate logistic regression analysis indicated CYP3A4 and CYP3A5 polymorphisms as significant factors involved in the therapeutic effect of Tac (Table 4). For these polymorphisms, a multivariate logistic regression model after adjusting for age and p-Mayo revealed both CYP3A4 and CYP3A5 polymorphisms as significant factors affecting the therapeutic effects of Tac with similar odds ratios (ORs): CYP3A4*1/*1 (OR: 0.15,

https://doi.org/10.1371/journal.pone.0250597.g001

**Fig 1. Response rate of patients with CYP3A4 and CYP3A5 polymorphisms after tacrolimus initiation.** Panel A shows the response rate of patients with CYP3A4 polymorphisms at 1, 2, and 4 weeks after Tac treatment, and panel B shows that of patients with CYP3A5 polymorphisms. Clinical response was defined as a partial Mayo score reduction of ≥2 points accompanied by a decrease of at least 30% from baseline and a decrease in the rectal bleeding subscore of ≥1 or an absolute rectal bleeding subscore of 0 or 1. CYP3A4: cytochrome P450 family 2 subfamily A member 4; CYP3A5: cytochrome P450 family 2 subfamily A member 5.
95% confidence interval (CI): 0.04–0.64, P = 0.010) and CYP3A5 non-expressers (OR: 0.16, 95% CI: 0.04–0.71, P = 0.016) (Table 5).

Association between gene polymorphisms and adverse events

Fifty-three adverse events were observed over 12 weeks. There were no serious adverse events. The most frequent events were renal impairment (n = 14), followed by hypomagnesemia (n = 12), hyperkalemia (n = 6), and neuropathy (n = 5) (S2 Table). Individuals with the NR1I2–25385C/C genotype presented significantly more events than those with the C/T or T/T genotype for all events (P = 0.03) (Table 6). There was no association between the other gene polymorphisms and adverse events.
Discussion

This retrospective study showed that CYP3A4*1G and CYP3A5*3 polymorphisms affected the pharmacokinetics and therapeutic effect of Tac in patients with UC. The effect of CYP3A5 polymorphism on Tac pharmacokinetics was strong compared with that of CYP3A4 polymorphism. Furthermore, the NR1I2–25385 genotype was related to the overall adverse events, implicating that this polymorphism might be a potential predictor of the adverse events of Tac therapy.

Table 5. Multivariate analysis of factors associated with efficacy at 1 week after tacrolimus treatment.

| Gene   | Position | Genotype                  | n  | All adverse events | Renal impairment | Hypomagnesemia |
|--------|----------|---------------------------|----|--------------------|------------------|----------------|
|        |          |                           |    |                     | n (%) P value    | n (%) P value  | n (%) P value |
| CYP3A4 | *1G      | *1/*1                      | 30 | 21 (70)             | 0.53            | 9 (30)         | 1.00           | 6 (20)         | 0.29 |
|        |          | *1/*1 + *1G                | 15 | 9 (60)              |                 | 5 (33)         |                | 6 (40)         |     |
|        |          | *1/*1G                     |    |                     |                 |                |                |                |     |
| CYP3A5 | *3       | *1/*1 + *1/*3              | 13 | 7 (54)              | 0.50            | 5 (38)         | 0.50           | 4 (31)         | 0.72 |
|        |          | *3/*3                      | 32 | 22 (69)             |                 | 9 (28)         |                | 8 (25)         |     |
| CYP2C19| *2       | GG                         | 28 | 19 (68)             | 1.00            | 9 (32)         | 1.00           | 6 (21)         | 0.28 |
|        |          | GA + AA                    | 17 | 11 (65)             |                 | 5 (29)         |                | 5 (29)         |     |
|        |          | *3                         | 35 | 24 (69)             | 0.71            | 11 (31)        | 1.00           | 11 (31)        | 0.09 |
|        |          | GA + AA                    | 10 | 6 (6)               | 3 (30)          |                | 0              |                |     |
| ABCC2  | −24      | CC                         | 32 | 22 (69)             | 0.73            | 10 (31)        | 1.00           | 7 (22)         | 0.70 |
|        |          | CT + TT                    | 13 | 8 (62)              |                 | 4 (31)         |                | 4 (31)         |     |
|        |          | *24                        |    |                     |                 |                |                |                |     |
|        |          | 1249                       | 34 | 22 (65)             | 0.73            | 10 (29)        | 0.72           | 8 (24)         | 1.00 |
|        |          | GA + AA                    | 11 | 8 (73)              |                 | 4 (36)         |                | 3 (27)         |     |
|        |          | *3972                      | 30 | 21 (70)             | 0.52            | 9 (30)         | 1.00           | 7 (23)         | 1.00 |
|        |          | CT + TT                    | 15 | 9 (60)              |                 | 5 (33)         |                | 4 (27)         |     |
| NR1I2  | −25385   | CC                         | 26 | 21 (81)             | 0.03*           | 9 (35)         | 0.75           | 6 (23)         | 1.00 |
|        |          | CT + TT                    | 19 | 9 (47)              |                 | 5 (26)         |                | 5 (26)         |     |

* = P < 0.05, ** = P < 0.01, *** = P < 0.001

CI: confidence interval; CYP3A4: cytochrome P450 family 2 subfamily A member 4; CYP3A5: cytochrome P450 family 2 subfamily A member 5; OR: odds ratio

https://doi.org/10.1371/journal.pone.0250597.t005

Table 6. Association between gene polymorphisms and adverse events.

| Gene   | Position | Genotype | n  | All adverse events | Renal impairment | Hypomagnesemia |
|--------|----------|----------|----|--------------------|------------------|----------------|
|        |          |          |    |                     | n (%) P value    | n (%) P value  | n (%) P value |
| CYP3A4 | *1G      | *1/*1    | 30 | 21 (70)             | 0.53            | 9 (30)         | 1.00           | 6 (20)         | 0.29 |
|        |          | *1/*1G   | 15 | 9 (60)              |                 | 5 (33)         |                | 6 (40)         |     |
|        |          | *1/*1G   |    |                     |                 |                |                |                |     |
| CYP3A5 | *3       | *1/*1 + *1/*3 | 13 | 7 (54)              | 0.50            | 5 (38)         | 0.50           | 4 (31)         | 0.72 |
|        |          | *3/*3    | 32 | 22 (69)             |                 | 9 (28)         |                | 8 (25)         |     |
| CYP2C19| *2       | GG       | 28 | 19 (68)             | 1.00            | 9 (32)         | 1.00           | 6 (21)         | 0.28 |
|        |          | GA + AA  | 17 | 11 (65)             |                 | 5 (29)         |                | 5 (29)         |     |
|        |          | *3       | 35 | 24 (69)             | 0.71            | 11 (31)        | 1.00           | 11 (31)        | 0.09 |
|        |          | GA + AA  | 10 | 6 (6)               | 3 (30)          |                | 0              |                |     |
| ABCC2  | −24      | CC       | 32 | 22 (69)             | 0.73            | 10 (31)        | 1.00           | 7 (22)         | 0.70 |
|        |          | CT + TT  | 13 | 8 (62)              |                 | 4 (31)         |                | 4 (31)         |     |
|        |          | *24      |    |                     |                 |                |                |                |     |
|        |          | 1249     | 34 | 22 (65)             | 0.73            | 10 (29)        | 0.72           | 8 (24)         | 1.00 |
|        |          | GA + AA  | 11 | 8 (73)              |                 | 4 (36)         |                | 3 (27)         |     |
|        |          | *3972    | 30 | 21 (70)             | 0.52            | 9 (30)         | 1.00           | 7 (23)         | 1.00 |
|        |          | CT + TT  | 15 | 9 (60)              |                 | 5 (33)         |                | 4 (27)         |     |
| NR1I2  | −25385   | CC       | 26 | 21 (81)             | 0.03*           | 9 (35)         | 0.75           | 6 (23)         | 1.00 |
|        |          | CT + TT  | 19 | 9 (47)              |                 | 5 (26)         |                | 5 (26)         |     |

* = P < 0.05, ** = P < 0.01, *** = P < 0.001

ABCC2: ATP-binding cassette subfamily C member 2; CYP2C19: cytochrome P450 family 2 subfamily C member 19; CYP3A4: cytochrome P450 family 2 subfamily A member 4; CYP3A5: cytochrome P450 family 2 subfamily A member 5; NR1I2: nuclear receptor subfamily 1 group I member 2

https://doi.org/10.1371/journal.pone.0250597.t006
Approximately 15% of UC patients have been reported to develop an acute severe colitis, which sometimes requires urgent/emergency surgery owing to major complications such as perforation, toxic megacolon, and massive hemorrhage [30]. The therapeutic range of the Tac trough level, which is 10–15 ng/mL for an induction period of 1 week in Japan [31], is narrow; therefore, close monitoring of the Tac trough level is necessary to achieve the optimum concentration as fast as possible and reduce the risk of emergency colectomy. Recently, Okabayashi et al. showed that the individualized dosage adjustment of Tac based on CYP3A5 polymorphisms could be useful to quickly achieve a high Tac trough level and early therapeutic efficacy [32]. The principle of this strategy is that Tac is primarily metabolized by the biotransformation enzymes CYP3A4 and CYP3A5 in the liver and gut, and this affects its blood concentration [4]; moreover, CYP3A5 polymorphisms were used because they are reported to affect the pharmacokinetics of Tac. Furthermore, organ transplantation studies have reported that CYP3A5 expressers (CYP3A5*1/*1+/*1/*3) have a significantly higher Tac metabolic capacity than CYP3A5 non-expressers (CYP3A5*3/*3) [33–35]. Onodera et al. showed that among UC patients, the C/D ratio of Tac was significantly lower in CYP3A5 expressers than in CYP3A5 non-expressers at 7–10 days after reaching a high trough level [36]. Hirai et al. also reported that CYP3A5-expressing patients with UC required a longer time to reach the effective blood concentration than CYP3A5 non-expressers [37]. Consistent with these previous findings, in the present study, CYP3A5-expressers required a significantly longer duration and significantly higher Tac dose and C/D ratio than CYP3A5 non-expressers.

In addition, the effects of CYP3A4 polymorphisms on the blood concentration and clinical efficacy of Tac are controversial, especially in patients with UC. In the present study, we revealed the frequency of CYP3A4*1G polymorphisms, which could affect the enzyme activity of CYP3A4 [38] and regulate the metabolism of several drugs in Japanese patients with UC, and their correlation with the pharmacokinetics and clinical efficacy of Tac. The allele frequency of CYP3A4*1G was 19%, which is consistent with that reported previously, that is, 18.8%–23% in the Chinese population [39, 40] and 24.9% in the Japanese population [22]. Although the frequency of CYP3A4*1G polymorphisms is relatively high in East Asia, there are only a few reports on the relationship between CYP3A4*1G polymorphisms and Tac pharmacokinetics. Uesugi et al. reported that the Tac C/D ratio of patients with CYP3A4*1/*1G transplanted liver was significantly lower in the first 1 week after surgery than in patients with CYP3A4*1/*1 [41]. Li et al. reported that the C/D ratio of Tac in patients with CYP3A4*1/*1 was significantly higher on day 7 after renal transplantation than that in patients with the CYP3A4*1G allele [24]. In the present study, patients with the CYP3A4*1G allele required a significantly longer duration than those with CYP3A4*1/*1. The C/D ratio was significantly lower in patients with the CYP3A4*1G allele than in those with CYP3A4*1/*1.

Regarding the effect of these gene polymorphisms on the therapeutic efficacy of Tac, the response rate at 1 week after Tac initiation in the present study was significantly higher in patients with UC with CYP3A5*3/*3 than in those with the CYP3A5*1 allele, consistent with the findings of a previous study [37] although some studies have not shown significant results in terms treatment efficacy [32, 36, 42]. Furthermore, in the present study, patients with CYP3A4*1/*1 showed a higher response rate than those with CYP3A4*1G. Therefore, we concluded that the CYP3A5*3 polymorphisms are independent predictors of early therapeutic effects.

However, in accordance with the findings of previous studies [18, 22], our study showed that CYP3A5*3 and CYP3A4*1G polymorphisms had a strong LD relationship. Because of this LD, it is difficult to accurately evaluate the effect of CYP3A4*1G polymorphism on the pharmacokinetics and clinical efficiency of Tac. These two polymorphisms are not perfect, but are strongly related to each other. In fact, the CYP3A4*1G polymorphism has been reported to
Contribute to the difference of individual in Tac pharmacokinetics among CYP3A5 expressers [18] and could help regulate the amount of Tac among CYP3A5 non-expressers [24]. In the present study, all CYP3A5 expressers carried the CYP3A4*1G allele. Moreover, among 15 patients with the CYP3A4*1G allele, CYP3A5 expressers showed a significantly lower C/D ratio than CYP3A5 non-expressers, suggesting that CYP3A5 polymorphisms could have a stronger effect on Tac pharmacokinetics. However, because of the small sample size of the present study, further large-scale studies are needed to better understand this metabolic pathway.

Regarding safety, although several studies have shown that the CYP3A5*3 polymorphism is related to nephrotoxicity, there is not enough consensus [42–46]. Asada et al. reported that the incidence of overall adverse events and nephrotoxicity was significantly higher in CYP3A5 expressers than in CYP3A5 non-expressers [42]. In the present study, there was no significant relationship between adverse events, including nephrotoxicity, and CYP3A5*3 polymorphism, whereas patients with the NR1I2−25385C/C genotype presented significantly more overall adverse events than those with the NR1I2−25385T genotype. However, the mechanism cannot be explained by our findings as this polymorphism and adverse events were not related to the blood Tac trough levels. NR1I2 63396TT polymorphisms have been reported to be a risk factor for peripheral neuropathy in patients co-infected with human immunodeficiency virus and Mycobacterium tuberculosis [47]. Li et al. revealed that severe liver injury could be caused by certain drugs via PXR-mediated alteration of the heme biosynthesis pathway in PXR (encoded by NR1I2)-humanized mice [48]. Therefore, further functional studies on the effect of NR1I2 on Tac treatment might provide useful information.

The present study had some limitations. First, this was a retrospective single-center study that comprised a small number of patients. The statistical analysis of the relationship between pharmacokinetics and CYP3A4*1/*1 polymorphism along with CYP3A4*1G polymorphism could not be performed owing to the small number of patients. Second, measurement immunoassays of blood Tac concentration changed over the study period, which might affect concentration data. Third, the power to detect adverse events was insufficient because we only examined medical records. Fourth, except CYP, NR1I2, and ABCC, we did not investigate other enzymes involved in Tac metabolism, which might lead to missing potential confounding SNPs.

In conclusion, although we found that CYP3A4*1G and CYP3A5*3 polymorphisms were related to Tac pharmacokinetics, CYP3A5 polymorphism could have a stronger effect than CYP3A4, suggesting that these polymorphisms can be used to predict the short-term therapeutic effects of Tac. The NR1I2−25385C/C genotype was related to overall adverse events, whereas CYP3A4*1G and CYP3A5*3 were not, suggesting that NR1I2 polymorphism might be a potential predictor of the adverse events caused by Tac therapy. The evaluation of these polymorphisms could provide useful information on the status of Tac treatment in patients with UC. However, due to the small number of cases in this study, we hope that further external verification of clinical usefulness will be performed.

Supporting information
S1 Table. Combination of CYP3A4 and CYP3A5 gene polymorphisms. (PDF)
S2 Table. Adverse event summary. (PDF)
Acknowledgments

All authors agree with this submission. SH and KW made substantial contributions to the concept of this study. MF, SH, YN, and SI made substantial contributions to data and sample acquisition. MF and SH made substantial contributions to the data analysis. MF and SH made substantial contributions to manuscript writing. Yuji Nadatani, SH, KO, FN, Yasuaki Nagami, KT, NK, TW, KW, and YF made substantial contributions to reviewing and editing this manuscript.

Author Contributions

Conceptualization: Shuhei Hosomi, Kenji Watanabe.

Data curation: Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani.

Formal analysis: Maizumi Furuse, Shuhei Hosomi.

Writing – original draft: Maizumi Furuse.

Writing – review & editing: Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yusuhito Fujiwara.

References

1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017; 389(10080):1756–70. https://doi.org/10.1016/S0140-6736(16)32126-2 PMID: 27914657

2. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5(1):103–10. https://doi.org/10.1016/j.cgh.2006.09.033 PMID: 17142106

3. Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2016; 10(4):484–94. https://doi.org/10.1093/ ecco-jcc/jjv221 PMID: 26645641

4. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol. 1994; 47(4):727–35. https://doi.org/10.1016/0006-2952(94)90136-8 PMID: 7510480

5. Zhang HF, Wang HH, Gao N, Wei JY, Tian X, Zhao Y, et al. Physiological Content and Intrinsic Activities of 10 Cytochrome P450 3A Isoforms in Human Normal Liver Microsomes. J Pharmacol Exp Ther. 2016; 358(1):83–93. https://doi.org/10.1124/jpet.116.233635 PMID: 27189963

6. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015; 98(1):19–24. https://doi.org/10.1002/cpt.113 PMID: 25801146

7. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27(4):383–91. https://doi.org/10.1038/86882 PMID: 11279519

8. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics. 2004; 5(3):243–72. https://doi.org/10.1517/phgs.5.3.243.29833 PMID: 15102541

9. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics. 2004; 14(7):471–8. https://doi.org/10.1097/01.fpc.0000114747.98559.49 PMID: 15228679

10. Haufroid V, Wallermaq P, VanKerkhove V, Elens L, De Meyer M, Edour DC, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant. 2006; 6(11):2706–13. https://doi.org/10.1111/j.1600-6143.2006.01518.x PMID: 17049058

11. Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006; 16(9):659–65. https://doi.org/10.1097/01.fpc.0000220571.20961.dd PMID: 16996020
12. Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics. 2015; 16(18):2045–54. https://doi.org/10.2217/pgs.15.138 PMID: 26615671

13. Hu R, Barratt DT, Coller JK, Salustio BC, Somogyi AA. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenet Genomics. 2019; 29(1):9–17. https://doi.org/10.1097/FTD.0000000000000360 PMID: 30489455

14. Hannachi I, Fredj NB, Chadli Z, Fadhel NB, Romdhane HB, Toutilou Y, et al. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicol Appl Pharmacol. 2020; 396:115000. https://doi.org/10.1016/j.taap.2020.115000 PMID: 32275916

15. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001; 29(3):268–73. PMID: 11181494

16. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single-nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005; 6(4):357–71. https://doi.org/10.1015/14622416.6.4.357 PMID: 16004554

17. Wang CE, Lu KP, Chang Z, Guo ML, Qiao HL. Association of CYP3A4*1B with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis. Gene. 2018; 664:44–9. https://doi.org/10.1016/j.gene.2018.04.043 PMID: 29678659

18. Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics. 2011; 12(7):977–84. https://doi.org/10.2217/pgs.11.33 PMID: 21635144

19. Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013; 23(5):251–61. https://doi.org/10.1097/ FPC.0b1013e32835f6cb3 PMID: 23459029

20. He BX, Shi L, Qiu J, Zeng XH, Zhao SJ. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease. J Clin Pharmacol. 2014; 54(4):462–7. https://doi.org/10.1002/jcph.229 PMID: 24214373

21. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013; 38(3):349–54. https://doi.org/10.2131/jts.38.349 PMID: 23665933

22. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2004; 23(1):100. https://doi.org/10.1002/humu.9210 PMID: 14695543

23. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al. The human pregnancy X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenet Genomic. 2001; 11(7):555–72. https://doi.org/10.1097/00008571-200110000-00003 PMID: 11668216

24. Li JL, Liu S, Fu Q, Zhang Y, Wang XD, Liu XM, et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR112 polymorphisms on tacrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015; 16(12):1355–65. https://doi.org/10.2217/pgs.15.178 PMID: 26228923

25. Iwamoto T, Monma F, Fujiyeda K, Nakatani K, Gayle AA, Nobori T, et al. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation. Ther Drug Monit. 2015; 37(5):581–8. https://doi.org/10.1097/FTD.0000000000000182 PMID: 25565672

26. Imamura CK, Furihata K, Okamoto S, Tanigawara Y. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol. 2016; 56(4):408–13. https://doi.org/10.1002/jcph.605 PMID: 26239045

27. Ogasawara K, Chitinis SD, Gohr Ry, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013; 52(9):751–62. https://doi.org/10.1007/s40262-013-0069-2 PMID: 23633119

28. Genvigir FDV, Nishikawa AM, Felipe CR, Tedesco-Silva H Jr., Oliveira N, Salazar ABC, et al. Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy. 2017; 37(5):535–45. https://doi.org/10.1002/phar.1928 PMID: 28316087
29. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660–6. https://doi.org/10.1002/ibd.20520 PMID: 18623174

30. Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol. 2018;32–33:71–8. https://doi.org/10.1016/j.bpcg.2018.05.017 PMID: 30069491

31. Matsuoka K, Saito E, Fuji T, Takenaka K, Kimura M, Nagahori M, et al. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015;13(3):219–26. https://doi.org/10.5217/ir.2015.13.3.219 PMID: 26130996

32. Okabayashi S, Kobayashi T, Saito E, Toyonaga T, Ozaki R, Sagami S, et al. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intest Res. 2019;17(2):218–26. https://doi.org/10.5217/ir.2018.00117 PMID: 30704156

33. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004;78(8):1182–7. https://doi.org/10.1097/01.tp.0000137789.58694.b4 PMID: 15502717

34. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, et al. Association of MDR1, CYP3A4 18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2008; 64(11):1069–84. https://doi.org/10.1007/s00228-008-0520-8 PMID: 18636247

35. Liu F, Ou YM, Yu AR, Xiong L, Xin HW. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients. Genet Test Mol Biomarkers. 2017; 21(11):663–73. https://doi.org/10.1089/gtmb.2017.0088 PMID: 28945481

36. Onodera M, Endo K, Kuroha M, Kimura T, Hiramori K, et al. ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017; 32(9):1562–9. https://doi.org/10.1111/j.1440-1746.2017.08597.x PMID: 28135009

37. Hirai F, Takatsu N, Yano Y, Satoh Y, Takahashi H, Ishikawa S, et al. Individualized treatment of tacrolimus and genetic variability: a review. Ann Transplant. 2012; 17(2):111–21. https://doi.org/10.12659/aot.883229 PMID: 22743729

38. He BX, Shi L, Qiu J, Tao L, Li R, Yang L, et al. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol. 2011; 108(3):208–13. https://doi.org/10.1111/j.1742-7843.2010.00657.x PMID: 21199372

39. Yuan R, Zhang X, Deng Q, Wu Y, Xiang G. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta. 2011; 412(9–10):755–88. https://doi.org/10.1016/j.cca.2010.12.038 PMID: 21223952

40. Yuan JJ, Hou JK, Zhang W, Chang YZ, Li ZS, Wang ZY, et al. CYP3A4 + 1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients. Pharmacology. 2015; 96(1–2):55–60. https://doi.org/10.1159/000433441 PMID: 26087974

41. Uesugi M, Hosokawa M, Shinkle H, Hashimoto E, Takahashi T, Kawai T, et al. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull. 2013; 36(11):1814–21. https://doi.org/10.1248/bpb.b13-00509 PMID: 24189425

42. Asada A, Bamba S, Morita Y, Takahashi K, Imaeda H, Nishida A, et al. The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus. Dig Liver Dis. 2017; 49(1):24–8. https://doi.org/10.1016/j.dld.2016.09.008 PMID: 27717793

43. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeken K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 2010; 32(4):394–404. https://doi.org/10.1097/FTD.0b013e3181e06818 PMID: 20526235

44. Gijzen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant. 2012; 17(2):111–21. https://doi.org/10.12659/aot.883229 PMID: 22743729

45. Quteinieh L, Verstuyft C, Furlan V, Durbach A, Letierce A, Ferlicot S, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008; 103(6):546–52. https://doi.org/10.1111/j.1742-7843.2008.00327.x PMID: 19067682

46. Klauke B, Wirth A, Zittermann A, Bohms B, Tenderich G, Korfer R, et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation.
47. Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, et al. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clin Pharmacol Ther. 2019; 106(2):450–7. https://doi.org/10.1002/cpt.1403 PMID: 30779340

48. Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 2013; 19(4):418–20. https://doi.org/10.1038/nm.3104 PMID: 23475203